Key Highlights
- LRCX reached a record peak of $275.99, climbing 5.56% in a single session
- Annual returns reached 252% over the trailing twelve months
- Analyst price targets now span from $310 through $340
- Neil Fernandes, SVP, executed a $4.6M stock sale on May 1 through a pre-arranged 10b5-1 plan
- Export controls targeting China’s Hua Hong create potential regulatory challenges
Lam Research (LRCX) achieved a record high of $275.99 during trading on May 5, 2026, posting gains exceeding 5.5% for the session. This milestone caps a remarkable twelve-month period where the stock delivered 252% in total returns, elevating the semiconductor equipment maker’s market capitalization to $343 billion.
Lam Research Corporation, LRCX
Top-line revenue expanded approximately 27% across the trailing twelve-month period. The company earned a Piotroski Score of 9, representing the highest possible reading on this financial strength metric monitored by InvestingPro.
Shares currently command a P/E ratio of 48.75. According to InvestingPro’s valuation framework, LRCX appears to trade above its calculated Fair Value benchmark.
Analyst activity has intensified in recent weeks. Stifel elevated its price target to $325 following fiscal Q3 earnings that surpassed both the firm’s projections and Street consensus. The Buy rating remains intact.
TD Cowen pushed expectations higher still, setting a $340 target. The firm highlighted competitive advantages in foundry and DRAM markets, alongside anticipated expansion in NAND wafer fabrication equipment expenditures.
Cantor Fitzgerald maintained its Overweight stance while setting a $320 price objective. The firm referenced an enhanced outlook for wafer fabrication equipment spending extending through calendar 2026, with industry expansion forecasted at a minimum of 27%.
UBS preserved its Buy recommendation at a $310 target, identifying LRCX as positioned for an AI-powered expansion phase.
Executive Stock Transaction
Senior Vice President Neil Fernandes divested 18,170 shares on May 1 at $255.14 per share, generating proceeds of approximately $4.64 million. This transaction occurred under a Rule 10b5-1 trading arrangement established by Fernandes on November 17, 2025.
Following this sale, Fernandes maintains direct ownership of 66,129 shares. Additional indirect holdings include slightly more than 1,015 shares held in a 401(k) account.
Executives regularly utilize pre-arranged trading plans of this nature, which typically remain neutral regarding future stock performance expectations.
Export Restrictions Create Headwinds
Regulatory challenges have emerged on the horizon. The U.S. Department of Commerce enacted export limitations affecting chip equipment deliveries to Hua Hong, ranked as China’s second-largest semiconductor manufacturer. Lam Research appeared among the American equipment suppliers subject to these constraints.
These restrictions initially prompted declines across chip equipment stocks when first announced. The full revenue implications for LRCX stemming from these trade policies remain under assessment.
Fiscal Q4 guidance exceeded market expectations. The company has already achieved margin and revenue benchmarks originally targeted for calendar year 2028.
LRCX’s fiscal Q3 performance topped both Stifel’s estimates and broader Wall Street forecasts, catalyzing the current round of price target increases from analysts.
Shares concluded trading on May 5 at the record level of $275.99.
